Harbor Capital Advisors’s Intellia Therapeutics NTLA Stock Holding History

Harbor Capital Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-67,282	Closed	-$785K	–	1493
2024 Q4	$785K	Sell	67,282 -11,923	-15%	-$186K	0.03%	484
2024 Q3	$1.63M	Buy	79,205 +32,893	+71%	+$758K	0.07%	360
2024 Q2	$1.04M	Sell	46,312 -4,938	-10%	-$118K	0.08%	345
2024 Q1	$1.41M	Buy	51,250 +31,866	+164%	+$885K	0.18%	143
2023 Q4	$591K	Buy	19,384 +2,780	+17%	+$79.9K	0.11%	221
2023 Q3	$525K	Buy	16,604 +2,610	+19%	+$101K	0.11%	218
2023 Q2	$571K	Buy	13,994 +390	+3%	+$15.8K	0.11%	213
2023 Q1	$507K	Buy	13,604 +4,718	+53%	+$185K	0.15%	142
2022 Q4	$310K	Buy	+8,886	New	+$423K	0.3%	71

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Harbor Capital Advisors's NTLA Position: Q1 2025 in Review

Harbor Capital Advisors sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 67,282 shares — an estimated $785K sold.

Harbor Capital Advisors first reported a position in NTLA in Q4 2022 and held it in 9 quarters. The position peaked at $1.63M in Q3 2024. 294 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

Harbor Capital Advisors reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
Harbor Capital Advisors sold 67,282 Intellia Therapeutics shares in Q1 2025, an estimated $785K.
Harbor Capital Advisors first reported a position in Intellia Therapeutics in Q4 2022 and held it in 9 quarters.
Harbor Capital Advisors's Intellia Therapeutics position peaked at $1.63M in Q3 2024.
294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Harbor Capital Advisors's 13F filing for Q1 2025, filed 14 Apr 2025.